Literature DB >> 27118291

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Alexander A Leung1, Kara Nerenberg2, Stella S Daskalopoulou3, Kerry McBrien4, Kelly B Zarnke5, Kaberi Dasgupta3, Lyne Cloutier6, Mark Gelfer7, Maxime Lamarre-Cliche8, Alain Milot9, Peter Bolli10, Guy Tremblay11, Donna McLean12, Sheldon W Tobe13, Marcel Ruzicka14, Kevin D Burns14, Michel Vallée15, G V Ramesh Prasad13, Marcel Lebel9, Ross D Feldman16, Peter Selby17, Andrew Pipe18, Ernesto L Schiffrin19, Philip A McFarlane20, Paul Oh21, Robert A Hegele22, Milan Khara23, Thomas W Wilson24, S Brian Penner25, Ellen Burgess26, Robert J Herman5, Simon L Bacon27, Simon W Rabkin28, Richard E Gilbert29, Tavis S Campbell30, Steven Grover31, George Honos32, Patrice Lindsay33, Michael D Hill34, Shelagh B Coutts35, Gord Gubitz36, Norman R C Campbell37, Gordon W Moe38, Jonathan G Howlett39, Jean-Martin Boulanger40, Ally Prebtani41, Pierre Larochelle8, Lawrence A Leiter42, Charlotte Jones43, Richard I Ogilvie44, Vincent Woo45, Janusz Kaczorowski46, Luc Trudeau47, Robert J Petrella48, Swapnil Hiremath49, Denis Drouin50, Kim L Lavoie51, Pavel Hamet52, George Fodor18, Jean C Grégoire53, Richard Lewanczuk12, George K Dresser54, Mukul Sharma55, Debra Reid56, Scott A Lear57, Gregory Moullec58, Milan Gupta59, Laura A Magee60, Alexander G Logan13, Kevin C Harris61, Janis Dionne61, Anne Fournier62, Geneviève Benoit63, Janusz Feber64, Luc Poirier65, Raj S Padwal66, Doreen M Rabi67.   

Abstract

Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 new recommendations, as well as revisions to 2 previous recommendations. In the diagnosis and assessment of hypertension, automated office blood pressure, taken without patient-health provider interaction, is now recommended as the preferred method of measuring in-office blood pressure. Also, although a serum lipid panel remains part of the routine laboratory testing for patients with hypertension, fasting and nonfasting collections are now considered acceptable. For individuals with secondary hypertension arising from primary hyperaldosteronism, adrenal vein sampling is recommended for those who are candidates for potential adrenalectomy. With respect to the treatment of hypertension, a new recommendation that has been added is for increasing dietary potassium to reduce blood pressure in those who are not at high risk for hyperkalemia. Furthermore, in selected high-risk patients, intensive blood pressure reduction to a target systolic blood pressure ≤ 120 mm Hg should be considered to decrease the risk of cardiovascular events. Finally, in hypertensive individuals with uncomplicated, stable angina pectoris, either a β-blocker or calcium channel blocker may be considered for initial therapy. The specific evidence and rationale underlying each of these recommendations are discussed. Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force will continue to provide annual updates.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27118291     DOI: 10.1016/j.cjca.2016.02.066

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  156 in total

1.  Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm.

Authors:  Samia Mora; C Lan Chang; M Vinayaga Moorthy; Peter S Sever
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

Review 2.  Hypertension in African Americans.

Authors:  Nomsa Musemwa; Crystal A Gadegbeku
Journal:  Curr Cardiol Rep       Date:  2017-10-28       Impact factor: 2.931

Review 3.  Treatment of Hypertension in Patients with Diabetes Mellitus: a Contemporary Approach.

Authors:  Ben Alencherry; Luke J Laffin
Journal:  Curr Cardiol Rep       Date:  2021-01-23       Impact factor: 2.931

4.  Rationale for Ambulatory and Home Blood Pressure Monitoring Thresholds in the 2017 American College of Cardiology/American Heart Association Guideline.

Authors:  Paul Muntner; Robert M Carey; Kenneth Jamerson; Jackson T Wright; Paul K Whelton
Journal:  Hypertension       Date:  2019-01       Impact factor: 10.190

Review 5.  Automated Office-Based Blood Pressure Measurement: an Overview and Guidance for Implementation in Primary Care.

Authors:  Romsai T Boonyasai; Erika L McCannon; Joseph E Landavaso
Journal:  Curr Hypertens Rep       Date:  2019-04-04       Impact factor: 5.369

6.  Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for pharmacists: An update.

Authors:  Yazid N Al Hamarneh; Sherilyn K D Houle; Raj Padwal; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2016-10-06

Review 7.  Prevalence of high blood pressure under 2017 ACC/AHA guidelines: a systematic review and meta-analysis.

Authors:  Peisheng Xiong; Zhixi Liu; Meijuan Xiong; Feng Xie
Journal:  J Hum Hypertens       Date:  2020-12-08       Impact factor: 3.012

8.  Measurement of blood pressure.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-02

9.  Relation of Diastolic Blood Pressure and Coronary Artery Calcium to Coronary Events and Outcomes (From the Multi-Ethnic Study of Atherosclerosis).

Authors:  Faisal Rahman; Mahmoud Al Rifai; Michael J Blaha; Khurram Nasir; Matthew J Budoff; Bruce M Psaty; Wendy S Post; Roger S Blumenthal; John W McEvoy
Journal:  Am J Cardiol       Date:  2017-08-08       Impact factor: 2.778

Review 10.  BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?

Authors:  Hemal Bhatt; Lama Ghazi; David Calhoun; Suzanne Oparil
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.